The term data fiduciary appears frequently in discussions around the Digital Personal Data Protection Act 2023, yet it remains poorly understood within pharma organisations. Many teams assume it is a legal classification with limited relevance to day-to-day marketing or doctor engagement activities.
In reality, data fiduciary status directly affects how doctor data is collected, stored, shared, and activated across pharma marketing workflows. It determines who is accountable when consent is missing, when data is misused, or when audits occur.
This article explains the meaning of data fiduciary under DPDP Act using doctor data as the central example, because doctor engagement represents one of the most common and risk-exposed data use cases in pharma.
Under the DPDP Act, a data fiduciary is the organisation that decides why personal data is processed and how that processing happens.
This definition focuses on decision-making authority, not technical execution. The entity that defines the purpose of data use and controls how data flows through systems is treated as the data fiduciary.
In pharma, decisions about doctor engagement are almost always made internally. Marketing teams decide campaign objectives. Medical teams decide content. Commercial teams decide segmentation and targeting. Technology teams choose platforms and tools.
Because these decisions originate within the pharma company, the pharma company functions as the data fiduciary.
Doctor data is one of the most widely used datasets in pharma marketing. It includes names, phone numbers, email addresses, clinic details, specialties, locations, engagement history, and digital interaction data.
All of this information can identify an individual doctor. Under DPDP, this makes it personal data.
The moment a pharma company decides to use doctor data for communication, analytics, or engagement, it is exercising control over personal data processing. This is the defining characteristic of a data fiduciary.
A frequent assumption is that doctor data is exempt from data protection rules because it is professional in nature.
DPDP does not recognise this distinction.
If data can identify an individual, it is personal data, regardless of whether it is used in a professional context. Doctor data does not lose protection simply because it relates to medical practice or professional communication.
This is a critical shift from older practices and one that exposes gaps in many existing pharma marketing workflows.
Pharma companies act as data fiduciaries through everyday operational decisions.
They decide which doctors to include in campaigns. They define the purpose of engagement such as brand communication, medical education, or awareness initiatives. They select channels such as email, WhatsApp, digital platforms, or field force supported tools.
They also determine retention periods, access permissions, and deletion policies.
Even when agencies or vendors execute campaigns, these decisions remain with the pharma company. This is why fiduciary responsibility does not transfer.
Agencies and technology vendors often handle doctor data during campaign execution. This leads to confusion about their role.
Under DPDP, entities that process data on instructions from the data fiduciary are classified as data processors. They do not determine purpose independently.
In most pharma marketing arrangements, agencies follow briefs, targeting criteria, and approval workflows defined by the pharma company. They do not decide why the data is used.
As a result, agencies act as data processors, while the pharma company remains the data fiduciary.
Consent management is one of the clearest expressions of data fiduciary responsibility.
The data fiduciary must ensure that consent is obtained lawfully, recorded accurately, and enforced consistently. If a doctor withdraws consent, the fiduciary must ensure that processing stops across all systems.
This responsibility does not end at the CRM or campaign tool. Consent must propagate to agencies, analytics systems, and AI platforms.
Failure to enforce consent centrally exposes the data fiduciary to compliance risk.
Many doctor databases were built long before DPDP came into force. Consent records are often incomplete or not mapped to specific purposes.
As data fiduciaries, pharma companies must assess whether they are legally entitled to continue using this data. They must ensure that CRM systems support consent tracking, purpose mapping, and enforcement at the point of execution.
This is where DPDP-compliant HCP marketing architectures become essential, because they align data fiduciary obligations with real-world marketing workflows.
Audits reveal how fiduciary responsibility operates in practice.
When regulators or auditors ask how doctor data is used, they look for clear answers. Who decided the purpose? How was consent obtained? How is consent enforced? How is data shared with vendors?
These questions point back to the data fiduciary.
If records are fragmented or responsibilities unclear, the pharma company bears the consequences.
AI driven engagement systems rely on large volumes of doctor data. These systems often combine historical interaction data, behavioural signals, and predictive models.
As data fiduciaries, pharma companies must ensure that AI models are trained only on lawfully collected data. They must ensure that outputs align with the original purpose of data collection.
Consent withdrawal must be reflected across AI systems, not just in source databases. This requirement exposes weaknesses in legacy data architectures.
Ignoring data fiduciary responsibilities does not eliminate liability.
If doctor data is misused, if consent is missing, or if data is processed beyond its stated purpose, regulators will examine who made those decisions.
In most cases, this leads back to the pharma company.
Consequences may include penalties, audit findings, operational disruption, and reputational damage.
Effective response begins with clarity.
Pharma companies should document data purposes clearly. Consent mechanisms should be redesigned for explicitness and auditability. CRM and marketing systems should be evaluated for consent enforcement capability.
Teams across marketing, medical, IT, and legal should align on fiduciary responsibilities.
Treating data fiduciary obligations as a shared operational concern reduces long-term risk.
Data fiduciary is not a theoretical label. It defines accountability.
As data usage in pharma marketing becomes more sophisticated, fiduciary responsibilities increase. DPDP makes these responsibilities explicit and enforceable.
Understanding data fiduciary meaning using doctor data helps pharma leaders recognise where accountability truly lies.
Understanding data fiduciary meaning is essential for pharma companies operating under the DPDP Act. Doctor data is not just a marketing asset. It is regulated personal data that carries accountability.
Pharma organisations that accept and operationalise data fiduciary responsibility will be better positioned to scale engagement without regulatory friction.
If you are evaluating how to manage doctor data and HCP engagement as a data fiduciary under DPDP, this page explains how compliant, consent-first HCP marketing is being implemented in real pharma environments.